Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Boulware

Showing results (231-240 of 350) with videos related to

Pageof 35
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2020
Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal MeningitisMahsa Abassi, Ananta S Bangdiwala, Edwin Nuwagira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2020
Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus-Associated Tuberculous MeningitisEmily M Martyn, Ananta S Bangdiwala, Enock Kagimu, et al.
Open Forum Infectious Diseases|January 26, 2016
Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen SheddingDavid R Boulware, Maximilian von Hohenberg, Melissa A Rolfes, et al.
Open Forum Infectious Diseases|February 2, 2026
Development Framework of Desirability of Outcome Ranking Endpoints for Use in Clinical Trials of Invasive Fungal DiseasesJose Portugal Gonzales, Neil M Ampel, David R Boulware, et al.
Wellcome Open Research|February 7, 2022
Host Directed Therapies for Tuberculous MeningitisAngharad G Davis, Joseph Donovan, Marise Bremer, et al.
Open Forum Infectious Diseases|December 18, 2020
Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal MeningitisSupavit Chesdachai, Nicole W Engen, Joshua Rhein, et al.
Open Forum Infectious Diseases|September 12, 2022
Therapeutic Lumbar Punctures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?Enock Kagimu, Nicole Engen, Kenneth Ssebambulidde, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2020
Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin BCaleb P Skipper, Mucunguzi Atukunda, Anna Stadelman, et al.
Human Immunology|June 14, 2026
Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIVCaleb P Skipper, Biyue Dai, Bruno Borges, et al.
Mycoses|December 20, 2018
Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodiesNathan C Bahr, Anil A Panackal, Michelle M Durkin, et al.
Pageof 35

Showing results (231-240 of 350) with videos related to

Sort By:
Pageof 35
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2020
Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal MeningitisMahsa Abassi, Ananta S Bangdiwala, Edwin Nuwagira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2020
Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus-Associated Tuberculous MeningitisEmily M Martyn, Ananta S Bangdiwala, Enock Kagimu, et al.
Open Forum Infectious Diseases|January 26, 2016
Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen SheddingDavid R Boulware, Maximilian von Hohenberg, Melissa A Rolfes, et al.
Open Forum Infectious Diseases|February 2, 2026
Development Framework of Desirability of Outcome Ranking Endpoints for Use in Clinical Trials of Invasive Fungal DiseasesJose Portugal Gonzales, Neil M Ampel, David R Boulware, et al.
Wellcome Open Research|February 7, 2022
Host Directed Therapies for Tuberculous MeningitisAngharad G Davis, Joseph Donovan, Marise Bremer, et al.
Open Forum Infectious Diseases|December 18, 2020
Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal MeningitisSupavit Chesdachai, Nicole W Engen, Joshua Rhein, et al.
Open Forum Infectious Diseases|September 12, 2022
Therapeutic Lumbar Punctures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?Enock Kagimu, Nicole Engen, Kenneth Ssebambulidde, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2020
Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin BCaleb P Skipper, Mucunguzi Atukunda, Anna Stadelman, et al.
Human Immunology|June 14, 2026
Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIVCaleb P Skipper, Biyue Dai, Bruno Borges, et al.
Mycoses|December 20, 2018
Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodiesNathan C Bahr, Anil A Panackal, Michelle M Durkin, et al.
Pageof 35